- Home
- BLRX vs ALLR Comparison
BLRX vs ALLR Comparison
Compare BLRX & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLRX
- ALLR
- Stock Information
- Founded
- BLRX 2003
- ALLR 2004
- Country
- BLRX Israel
- ALLR United States
- Employees
- BLRX N/A
- ALLR N/A
- Industry
- BLRX Biotechnology: Pharmaceutical Preparations
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- BLRX Health Care
- ALLR Health Care
- Exchange
- BLRX Nasdaq
- ALLR Nasdaq
- Market Cap
- BLRX 17.1M
- ALLR 20.2M
- IPO Year
- BLRX 2011
- ALLR N/A
- Fundamental
- Price
- BLRX $3.40
- ALLR $1.18
- Analyst Decision
- BLRX Strong Buy
- ALLR Strong Buy
- Analyst Count
- BLRX 2
- ALLR 1
- Target Price
- BLRX $19.00
- ALLR $9.25
- AVG Volume (30 Days)
- BLRX 24.1K
- ALLR 227.2K
- Earning Date
- BLRX 11-24-2025
- ALLR 11-14-2025
- Dividend Yield
- BLRX N/A
- ALLR N/A
- EPS Growth
- BLRX N/A
- ALLR N/A
- EPS
- BLRX N/A
- ALLR N/A
- Revenue
- BLRX $12,735,000.00
- ALLR N/A
- Revenue This Year
- BLRX N/A
- ALLR N/A
- Revenue Next Year
- BLRX N/A
- ALLR N/A
- P/E Ratio
- BLRX N/A
- ALLR N/A
- Revenue Growth
- BLRX N/A
- ALLR N/A
- 52 Week Low
- BLRX $2.30
- ALLR $0.61
- 52 Week High
- BLRX $14.70
- ALLR $2.35
- Technical
- Relative Strength Index (RSI)
- BLRX 50.28
- ALLR 44.16
- Support Level
- BLRX $3.20
- ALLR $0.99
- Resistance Level
- BLRX $3.53
- ALLR $1.19
- Average True Range (ATR)
- BLRX 0.21
- ALLR 0.10
- MACD
- BLRX 0.03
- ALLR 0.00
- Stochastic Oscillator
- BLRX 93.02
- ALLR 51.12
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.